Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (L37606)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06101 - MAC A</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06102 - MAC B</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06201 - MAC A</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06202 - MAC B</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06301 - MAC A</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06302 - MAC B</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13101 - MAC A</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13102 - MAC B</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13202 - MAC B</td>
<td>J - K</td>
<td>New York - Downstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13282 - MAC B</td>
<td>J - K</td>
<td>New York - Upstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14111 - MAC A</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14112 - MAC B</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14211 - MAC A</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>CONTRACTOR NAME</td>
<td>CONTRACT TYPE</td>
<td>CONTRACT NUMBER</td>
<td>JURISDICTION</td>
<td>STATE(S)</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14212 - MAC B</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14311 - MAC A</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14312 - MAC B</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14411 - MAC A</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14412 - MAC B</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14511 - MAC A</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14512 - MAC B</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
</tbody>
</table>

### LCD Information

#### Document Information

**LCD ID**
L37606

**LCD Title**
Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases

**Proposed LCD in Comment Period**
N/A

**Source Proposed LCD**
DL37606

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**
CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

**Original Effective Date**
For services performed on or after 08/01/2018

**Revision Effective Date**
For services performed on or after 10/03/2019

**Revision Ending Date**
N/A

**Retirement Date**
N/A

**Notice Period Start Date**
06/14/2018

**Notice Period End Date**
07/31/2018
CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):
Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.
Section 1862(a)(7) excludes routine physical examinations, unless otherwise covered by statute.

CMS Publications:
CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 80.1 – Laboratory services must meet applicable requirements of CLIA
Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

**Acute Myelogenous Leukemia (AML)**

**Indications**

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:

- Newly diagnosed patients with AML who are undergoing induction therapy, and who are suitable candidates for post-induction transplantation or consolidation therapy at the time of testing, and meet one of the following cytogenetic criteria:
• normal karyotype
• core binding factor

Previously diagnosed patients with AML, who have not responded to induction chemotherapy, or who have progressed following induction. The patient must be a candidate for transplantation at the time of the testing.
• Patients with AML, who have responded to treatment, either chemotherapy or transplantation, with evidence of relapse.

Myelodysplastic Syndromes (MDS)

Indications

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:

• Patients with clinical signs or symptoms of myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN), in whom clinical, laboratory, and pathologic assessment are nondiagnostic.
• Newly diagnosed MDS or MDS/MPN patients either
  • stratified by the IPSS or IPSS-R as intermediate risk, or
  • in MDS with ringed sideroblasts/RARS.

Limitations

• Repeat Genomic Sequential Analysis Panel testing is not reasonable and necessary in MDS after initial diagnosis and risk stratification.

Myeloproliferative Neoplasms (MPN)

Indications and Limitations of Coverage

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following circumstances:

• **Diagnosis:** Clinical signs or symptoms of myeloproliferative neoplasm (MPN) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN) when
  • clinical, laboratory, and pathologic assessment are nondiagnostic; and
  • CML excluded (BCR-ABL1 negative)\(^1,2\)
• **Risk Stratification:** Newly diagnosed PMF not already classified as high-risk by Dynamic International Prognostic Scoring System (DIPSS) Plus\(^1,3,4\)
• **Monitoring:** Higher-risk MF (INT-1, INT-2, High-Risk) with progression on therapy\(^1\)
Summary of Evidence

**Acute Myelogenous Leukemia (AML)**

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts, primarily in the peripheral blood and bone marrow. The American Cancer Society estimates that approximately 60,000 new cases of leukemia will be diagnosed in 2016, with one-third classified as acute myelogenous leukemia (AML). It accounts for the most annual deaths from leukemia in the United States. The median age of diagnosis is 67, with 54% diagnosed at 65 years or older (and approximately one third diagnosed at 75 years of age or older). Moreover, AML lies at one end of a spectrum of neoplastic myeloid diseases that includes myelodysplastic syndromes (MDS), which often progress to AML, and which are even more common in patients of advanced age, with an incidence of approximately 1/5000 patients over the age of 70.

AML is an aggressive disease that requires immediate diagnosis and treatment, with an average 5 yr survival rate of 28%, depending on a number of clinical and biologic variables, including acquired genetic alterations within the leukemic cells. Early treatment of AML generally consists of high-dose cytotoxic chemotherapy to induce remission, followed by consolidation (i.e., post-remission) chemotherapy and/or bone marrow transplantation.

Steadily accumulating genomic evidence shows that certain acquired genetic alterations within the leukemic cells are strong predictors of prognosis in AML and, accordingly, are essential factors in the decision whether a patient should undergo bone marrow transplantation (1-4). These alterations have been set aside as determinants of independent diagnostic categories in WHO AML guidelines, and as essential for AML management in NCCN guidelines (5,6).

Importantly, the indication for molecular biomarkers in AML is somewhat different from other cancers, such as non-small cell lung cancer, in that the markers themselves are often not the direct targets of treatment. In AML, these molecular genetic biomarkers are incorporated into a risk-based treatment stratification that determines whether or not to recommend transplantation.

Moreover, AML patients often have multiple combinations of these essential mutations, again in contrast to the mutually exclusive driver oncogene alterations seen in solid cancers such as non-small cell lung cancer. In AML, the clinical effect of driver mutations can be modified by the wider genomic milieu, either additively or interactively (7). Therefore, complete assessment of AML patients requires testing multiple biomarkers concurrently, rather than a sequential single-biomarker approach. In this regard, panel testing is becoming the preferred approach.

**Myelodysplastic Syndromes (MDS)**

The myelodysplastic syndromes (MDS) represent a spectrum of clonal bone marrow diseases, with heterogeneous presentations that typically include one or more cytopenias, defective differentiation of blood cell progenitors into mature functional cells, and an increased rate of progression to acute myeloid leukemia (AML). These secondary AML cases carry a worse prognosis than de novo AML cases. Furthermore, there are myeloid neoplasms that share overlapping characteristics with both MDS and myeloproliferative neoplasms (MPNs), such as chronic myelomonocytic leukemia (CMML). The World Health Organization (WHO), has designated these diseases separately as MDS/MPNs, distinct from either MDS or MPNs (1).

According to the 2016 National Comprehensive Cancer Network (NCCN) Guidelines, the overall incidence of MDS is approximately 5/100,000 per year, primarily in adults. MDS is rare in patients under the age of 40, but much more common in older patients, with incidence of 30/100,000 among ages 70-79, and 60/100,000 in patients 80 years and older (2).
MDS treatment can range from surveillance/observation to high dose chemotherapy and bone marrow transplantation, with the principal determining factors being the patient's overall health and co-morbidities, and prognostic categorization.

MDS has historically been classified by a combination of traditional laboratory techniques, such as demonstration of stable cytopenias by complete blood count, microscopic examination of a bone marrow biopsy, and bone marrow cytogenetic studies. Other than the clinical feature of the number of cytopenias and specific cytogenetic changes found recurrently in MDS, all other diagnostic criteria in MDS rely upon light microscopy findings. These include the number of cell lineages (i.e., platelets, red blood cells, white blood cells) affected by dysplasia, the percentage of immature “blast” cells, and the presence or absence of a characteristic pattern of iron deposition in immature red blood cells called ring sideroblasts. Low risk MDS is associated with dysplasia affecting only one cell lineage, with or without ring sideroblasts, and isolated large deletions involving chromosome 5 (5q-). High risk disease is associated with dysplasia across multiple lineages, increased blast percentages, and complex karyotype. With the exception of SF3B1 mutations (see below), no specific mutations are incorporated into the current diagnostic criteria of MDS.

However, evidence has steadily accumulated over the first two decades of the 21st century showing that certain specific acquired genetic alterations within the myeloid cells are strong predictors of prognosis in MDS and, in the case of SF3B1, are necessary diagnostic markers as well (3-9). In addition, other somatic alterations may support the diagnosis of MDS in certain contexts. MDS can be challenging to diagnose, due to the subjective morphologic assessment of dysplasia, and a multitude of benign reactive conditions that can manifest as peripheral cytopenias and cytologic atypia that are especially prevalent in the elderly population. In this regard, the demonstration of these clonal molecular alterations in clinically and/or morphologically ambiguous cases can help establish a diagnosis of MDS and expedite therapy earlier in the disease course, before progression to a more overt, and life-threatening, condition. Accordingly, a number of specific genetic alterations are included in the NCCN guideline recommendations as necessary for the diagnosis and management of patients with MDS.

Forty-seven different gene mutations have been identified as recurring findings in MDS, including TET2, SF3B1, ASXL1, DNMT3A, SRSF2, RUNX1, TP53, U2AF1, EZH2, ZRSR2, STAG2, CBL, NRAS, JAK2, SETBP1, IDH1, IDH2, and ETV6. While some are more common than others, no single gene has been reported in more than approximately one-third of cases. Most of these are useful as adjunctive diagnostic markers for clinically/microscopically ambiguous cases, to help establish a more firm diagnosis and, potentially, as markers of clonal disease that can be used to monitor for disease progression and response to interventions.

Myeloproliferative Neoplasms (MPN)

The myeloproliferative neoplasms (MPNs) represent a group of rare clonal bone marrow diseases, have a median age at onset of 65-70 years, and heterogeneous presentations that typically include overgrowth of one or more of the myeloid cell lineages in the marrow, with increased circulation of mature forms in the peripheral blood, and an increased rate of progression to acute myeloid leukemia (AML). Symptomatology varies between the different diseases, typically related to the specific proliferating cell lineages.

MPNs can be subdivided in two main categories based upon the presence or absence of BCR-ABL1: chronic myeloid leukemia (CML) and non-CML MPNs. The main non-CML MPNs, also termed classical MPNs, including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV), had traditionally been defined by laboratory criteria such as thrombocytosis, marrow fibrosis, and erythrocytosis, respectively. Non-CML MPN treatment can range from observation to targeted therapies to hematopoietic stem cell transplantation (HCT), with the principal determining factors being the patient's overall health and co-morbidities, presence of fibrosis or increased blasts, molecular and prognostic categorization. Other less common diagnostic entities within the non-CML MPNs include chronic neutrophilic leukemia (CNL) and chronic eosinophilic leukemia (CEL).
While the definitions of the entities within MPN are fairly distinct, in practice, phenotypic overlap is common, and definitive classification can be challenging based solely on clinical grounds and traditional laboratory tests, such as complete blood count (CBC) and bone marrow biopsy. At diagnosis, the discrimination from reactive conditions is often critical, and the demonstration of several specific clonal molecular alterations in clinically or morphologically ambiguous cases can expedite an MPN diagnosis before progression to a more overt, life-threatening, condition. Accordingly, one or more MPN-restricted, driver mutations are included in practice guideline recommendations as necessary for the diagnosis or management of patients with MPN or MPN-like conditions, including Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus (MPL).\(^5\)\(^-\)\(^7\) Driver mutations are usually mutually exclusive.

JAK2 V617F mutations in exon 14 are the \textit{sine qua non} of PV, reported in >90% of cases. Another 2-3% have missense mutations or small insertion/deletions in a secondary hotspot of JAK2, in exon 12.\(^8\)\(^,\)\(^9\) The JAK2 V617F mutation is not specific within the MPNs, however, and has also been reported in approximately 40-60% of cases of ET and PMF. The JAK2 mutation is not present, however, in CML or in benign conditions that lead to secondary erythrocytosis and its presence is invaluable in this differential diagnosis.

Mutations in CALR exon 9, by contrast, are encountered in approximately 20-35% of patients with ET and PMF and are not characteristic of PV. Two alterations predominate: a 52 bp deletion (Type 1) that is more common in PMF or post-ET myelofibrosis, and a 5 bp insertion (Type 2) that is more common in ET, associated with more indolent disease and lower risk of thrombosis, despite an association with extremely high platelet counts. Beyond enabling a specific diagnosis, the presence of a CALR mutation portends a favorable prognosis in PMF (overall survival (OS) 17.7 years vs. 3.2 years with no mutations (“triple-negative” patients), and these patients have a lower rate of progression to AML over 10 years (9.4% vs. 34.4%).\(^10\) CALR mutation also is associated with improved overall survival (82% vs. 56% at 4 years) and non-relapse mortality (7% vs. 31%) following transplantation for PMF.\(^1\) The significance of CALR mutations in ET is dependent upon the type of mutation, as mentioned above, and less clear.

MPL mutations are another sequence alteration seen infrequently in ET and PMF, and predicts an increased risk of transfusion dependence in PMF.\(^10\) MPL mutations, like JAK2 and CALR, portends a favorable prognosis across MPN, when compared to triple negative MPN (approximately 10%) that lack mutations in any of these three genes.\(^1\)

In contrast to the favorable prognosis conferred by MPL, CALR, and JAK2, a number of other not MPN-restricted, non-driver, mutations are considered “high risk” for progressive disease and are associated with both a shorter OS and leukemic-free survival in PMF, including ASXL1, TET2, EZH2, SRSF2, SF3B1, SH2B3, U2AF1, TP53, IDH1, and IDH2.\(^1\)\(^,\)\(^5\)\(^,\)\(^6\) These co-mutated, myeloid genes additively contribute to phenotypic variability and shifts, as well as progression to more aggressive disease.\(^6\) Mutations in at least one of these genes confers a shortened median survival (81 vs. 148 months),\(^11\) and the presence of 2 or more of these mutations reduces median survival from 12.2 years to 2.6 years.\(^12\) However, a study of 570 patients with PMF demonstrated a counterbalancing effect of combining a low-risk mutation (CALR) with a high-risk mutation (ASXL1); the median OS was longest in CALR(+)/ASXL1(-) patients (10.4 years), shortest in CALR(-)/ASXL1(+) patients (2.3 years), and intermediate (5.8 years) when both are present or absent.\(^3\) In triple-negative patients, these non-driver mutations serve as a major diagnostic criteria for both PMF and ET. WHO and NCCN guidelines recommend analysis of mutations in these genes to assist in establishing an MPN diagnosis in the absence of mutations in MPL, CALR, and JAK2.\(^1\)\(^,\)\(^2\)

Moreover, patients with progressive MPNs are candidates for several different therapies, including hypomethylating agents, induction chemotherapy, HCT, and clinical trials. Selecting between these options is a complex determination that includes several factors, and NCCN recommends the analysis of mutations in ASXL1, EZH2, IDH1/2, SRSF2, and TP53 (category 2A) to assist in risk stratification and treatment planning in select PMF patients.\(^1\) Monitoring response to treatment is recommended every 3-6 months with additional molecular testing reserved for MF patients with INT-1-risk or INT-2-risk/high-risk disease to aid in decision-making regarding allogeneic HCT.\(^1\)
Analysis of Evidence
(Rationale for Determination)

Acute Myelogenous Leukemia (AML)
The spectrum of genetic abnormalities that are relevant in AML is broad, and includes specific sequence variants within genes, copy number changes, and structural variants such as chromosomal translocations. Smaller scale mutations require a molecular diagnostics method (e.g., sequencing) for analysis, while larger scale chromosomal abnormalities may be analyzed using either molecular diagnostics or cytogenetics (e.g., FISH, karyotype) methods. Molecular diagnostics and cytogenetic testing play a complementary role in helping refine prognosis, particularly in cytogenetically intermediate risk normal karyotype AML (NK-AML), or those with core binding factor where KIT mutations help refine the prognosis (6,8). The following molecular genetic biomarkers are considered necessary for diagnosis and management of AML.

Table 1 Biomarkers that require a molecular diagnostics method (either via panel or individually):

<table>
<thead>
<tr>
<th>Gene</th>
<th>Alteration</th>
<th>Clinical Utility</th>
<th>NCCN Biomarkers Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEBPA</td>
<td>Mutation</td>
<td>Favorable risk</td>
<td>2A</td>
</tr>
<tr>
<td>FLT3</td>
<td>Internal tandem duplication</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>KIT</td>
<td>Mutation</td>
<td>Intermediate risk</td>
<td>2A</td>
</tr>
<tr>
<td>NPM1</td>
<td>Insertion mutation</td>
<td>Favorable risk</td>
<td>2A</td>
</tr>
<tr>
<td>TP53</td>
<td>Mutations, deletions</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>RUNX1</td>
<td>Mutation</td>
<td>Distinct Diagnostic Category; Poor prognosis</td>
<td>*</td>
</tr>
</tbody>
</table>

* WHO 2016 AML Classification

These variants represent essential determinants of prognosis and therapy. As additional genetic variants are shown to similarly lead to safe and effective therapy selection and, therefore, meet Medicare coverage guidelines, additional genes may be added to Table 1.

Table 2 Biomarkers that can be assessed by either a molecular diagnostics method (panel only) or by a cytogenetics method:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Alteration</th>
<th>Clinical Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>PML-RARA</td>
<td>Rearrangement</td>
<td>All-trans retinoic acid</td>
</tr>
<tr>
<td>BCR-ABL1</td>
<td>Rearrangement</td>
<td>Poor risk</td>
</tr>
<tr>
<td>CBFB-MYH11</td>
<td>Rearrangement</td>
<td>Favorable risk</td>
</tr>
<tr>
<td>DEK-NUP214</td>
<td>Rearrangement</td>
<td>Poor risk</td>
</tr>
<tr>
<td>MLLT3-KMT2A</td>
<td>Rearrangement</td>
<td>Intermediate risk</td>
</tr>
<tr>
<td>Other KMT2A</td>
<td>Rearrangements</td>
<td>Poor risk</td>
</tr>
<tr>
<td>GATA2, MECOM</td>
<td>Rearrangement</td>
<td>Poor risk</td>
</tr>
<tr>
<td>RUNX1-RUNX1T1</td>
<td>Rearrangement</td>
<td>Favorable risk</td>
</tr>
<tr>
<td>Deletion 5, 5q</td>
<td>Copy number loss</td>
<td>Poor risk</td>
</tr>
<tr>
<td>Deletion 7, 7q</td>
<td>Copy number loss</td>
<td>Poor risk</td>
</tr>
<tr>
<td>Trisomy 8</td>
<td>Copy number gain</td>
<td>Intermediate risk</td>
</tr>
</tbody>
</table>

Myelodysplastic Syndromes (MDS)
Five of these genes (TP53, EZH2, ETV6, RUNX1, ASXL1) have established independent value as prognostic determinants, and a mutation in any one of these five genes indicates more aggressive disease, worsened overall survival, and confers a prognosis equivalent to one step worse in the Revised International Prognostic Scoring System (IPSS-R) (3-4). Several other genes, including DNMT3A, U2AF1, SRSF2, CBL, PRPF8, SETBP1, and KRAS, have been associated with decreased survival, although are not formally incorporated into treatment determinations per 2016 NCCN guidelines. Mutations in TET2 have been associated with improved response rate to hypomethylating agents, but not with response duration or overall survival and, therefore, alterations in this gene are not currently recommended as sole determinants of treatment with this class of agents. Other mutations associated with response to specific therapies (but not yet FDA approved) include SF3B1 mutations, which are associated with a favorable response to DNA methyl transferase inhibitors (DNMTI), SRSF2 mutations, which are associated with a poor response to DNMTIs, and TP53, which is associated with a poor response to lenalidomide.

Mutations in SF3B1 are associated with MDS with ringed sideroblasts (previously designated as refractory anemia with ringed sideroblasts (RARS)), which confers a favorable prognosis. In the revised WHO classification, this diagnosis is established by the finding of at least 15% ringed sideroblasts by light microscopy or by the presence of an SF3B1 mutation and at least 5% ringed sideroblasts.

The spectrum of genetic abnormalities that are relevant in MDS is broad, and includes specific sequence variants within a large number of genes as well as a wide range of aberrations in other genes. While it is possible to assess the former of these with single gene assays, it is functionally impractical given the number of hotspot variants and number of genes. The latter require more complete coverage of the entire gene. In this regard, MDS is an appropriate indication for multiplexed sequencing, which is typically performed by next generation sequencing. The following molecular genetic biomarkers are considered necessary for diagnosis and management of select MDS.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Clinical Utility</th>
<th>NCCN Biomarkers Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP53</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>EZH2</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>ETV6</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>ASXL1</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>RUNX1</td>
<td>Poor risk</td>
<td>2A</td>
</tr>
<tr>
<td>SF3B1</td>
<td>Low risk; diagnosis of MDS with ringed sideroblasts/RARS</td>
<td>2A</td>
</tr>
</tbody>
</table>

In total, the required nucleotide or small insertion/deletion variants occur at numerous specific loci in six genes. These variants represent essential determinants of prognosis and therapy. As additional genetic variants are shown to similarly lead to safe and effective therapy selection and, therefore, meet Medicare coverage guidelines, additional genes may be added to the above table.

**Myeloproliferative Neoplasms (MPN)**

The following molecular genetic biomarkers are considered necessary for diagnosis and management of select MPNs.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Clinical Utility</th>
<th>NCCN Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK2</td>
<td>Diagnosis, intermediate prognosis, higher risk of thrombosis</td>
<td>2A</td>
</tr>
<tr>
<td>CALR</td>
<td>Diagnosis, improved survival, lower risk of thrombosis</td>
<td>2A</td>
</tr>
<tr>
<td>MPL</td>
<td>Diagnosis, intermediate prognosis, lower risk of thrombosis</td>
<td>2A</td>
</tr>
</tbody>
</table>

Created on 01/03/2020. Page 10 of 13
In total, the required nucleotide or small insertion/deletion variants occur at numerous specific loci in eight genes. These variants represent essential determinants of prognosis and associated therapy. As additional genetic variants are shown to similarly lead to safe and effective therapy selection and, therefore, meet Medicare coverage guidelines, additional genes may be added to the above table.

### General Information

#### Associated Information

N/A

#### Sources of Information

N/A

#### Bibliography

**Acute Myelogenous Leukemia (AML)**


**Myelodysplastic Syndromes (MDS)**


**Myeloproliferative Neoplasms (MPN)**


## Revision History Information

<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/03/2019</td>
<td>R3</td>
<td>This LCD was converted to the new &quot;no-codes&quot; format. There has been no change in coverage with this LCD revision.</td>
<td>• Revisions Due To Code Removal</td>
</tr>
<tr>
<td>08/15/2019</td>
<td>R2</td>
<td>Consistent with Change Request 10901, all coding information, National coverage provisions, and Associated Information (Documentation Requirements, Utilization Guidelines) have been removed from the LCD and placed in the related Billing and Coding Article, A56793. There has been no change in coverage with this LCD revision.</td>
<td>• Provider Education/Guidance</td>
</tr>
<tr>
<td>08/01/2018</td>
<td>R1</td>
<td>Removed the following wording, &quot;effective for services rendered on or after 12/01/2017&quot; from the “ICD-10 Codes that Support Medical Necessity” sections- Group 1 and Group 2 paragraphs.</td>
<td>• Provider Education/Guidance</td>
</tr>
</tbody>
</table>

## Associated Documents

### Attachments

N/A

### Related Local Coverage Documents

Article(s)

- A56793 - Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
- A55974 - Response to Comments: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases

### Related National Coverage Documents

N/A

### Public Version(s)

- Updated on 09/24/2019 with effective dates 10/03/2019 - N/A
- Updated on 08/09/2019 with effective dates 08/15/2019 - 10/02/2019
- Updated on 08/01/2018 with effective dates 08/01/2018 - 08/14/2019
- Updated on 06/08/2018 with effective dates 08/01/2018 - N/A

### Keywords

N/A

Created on 01/03/2020. Page 13 of 13